ADMA Biologics (NASDAQ: ADMA) revenue
ADMA Biologics reported revenue of $510.2m for fiscal 2025, 19.6% more than in fiscal 2024 ($426.5m). Since fiscal 2016 its revenue has grown by 4,685.4%, an average growth of 53.7% a year.
ADMA Biologics has grown its revenue for 7 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2018, −25.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $510.2m | +19.6% | $191.4m | 37.5% |
| 2024 | $426.5m | +65.2% | $139.0m | 32.6% |
| 2023 | $258.2m | +67.6% | $21.6m | 8.4% |
| 2022 | $154.1m | +90.4% | −$39.4m | −25.5% |
| 2021 | $80.9m | +91.7% | −$58.4m | −72.1% |
| 2020 | $42.2m | +43.9% | −$64.9m | −153.8% |
| 2019 | $29.3m | +72.8% | −$41.4m | −141.1% |
| 2018 | $17.0m | −25.4% | −$60.3m | −354.9% |
| 2017 | $22.8m | +113.5% | −$39.3m | −172.7% |
| 2016 | $10.7m | — | −$17.3m | −162.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ADMA Biologics revenue compared with its sector
By revenue for its latest fiscal year, ADMA Biologics ranks 191st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; ADMA Biologics, 19.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 189th | Mirum Pharmaceuticals | $521.3m | 54.7% |
| 190th | Veracyte | $517.1m | 16.0% |
| 191st | ADMA Biologics | $510.2m | 19.6% |
| 192nd | Glaukos | $507.4m | 32.3% |
| 193rd | STLN | $502.7m | 27.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of ADMA Biologics
- How much revenue did ADMA Biologics make in fiscal 2025?
- ADMA Biologics reported revenue of $510.2m for fiscal 2025, compared with $426.5m in fiscal 2024.
- How much has the revenue of ADMA Biologics grown?
- Between fiscal 2016 and fiscal 2025 it went from $10.7m to $510.2m: 4,685.4% more, an average growth of 53.7% a year.
- What was the best year for revenue at ADMA Biologics?
- Of its last 10 fiscal years, fiscal 2025, with $510.2m.
- Where does ADMA Biologics rank in its sector by revenue?
- It ranks 191st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for ADMA Biologics come from?
- From the annual report (Form 10-K) that ADMA Biologics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ADMA Biologics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on ADMA Biologics: the ADMA Biologics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.